Navigation Links
Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ
Date:3/10/2009

LONG BRANCH, N.J., March 10 /PRNewswire/ -- The long-awaited speaking faculty for the September Pharma ChemOutsourcing Conference & Exhibition has been posted on the conference website reports Mark Alexay, President of Apaporis LLC, the organizer. The chemistry faculty is comprised of 100 speakers from pharmaceutical companies and increasingly, biotech companies with small molecule products in the pipeline.

The speaker list may be viewed at www.chemoutsourcing.com

Attendance was up 50% at the 2008 event and the organizers are already seeing similar growth for this year's show despite the marked downturn in the economy. The superior information and networking opportunities plus the remarkably diverse pharmaceutical company attendee profile help distinguish the show.

Speakers will be coming from large Pharma companies like Pfizer, Merck, Wyeth, J & J, Lilly, Schering, and GSK and from dozens of smaller companies like Alkermes, Cenomed Biosciences, Oscient Pharmaceuticals, Reata Pharmaceuticals, Anacor Pharmaceuticals, Pharmasset, Orexigen, Proteolix, Magen Biosciences, Fibrogen, BioMarin Pharmaceuticals, NovaDel Pharma, Inspire Pharmaceuticals, GPC Biotech, Theravance, Adolor, Cephalon, and Sepracor.

Emerging biotech company small molecule sourcing needs will be a focus of the 2009 conference with many sessions and panels to provide discussion around key topics for these small companies. Unlike Large Pharma "virtual" companies have very different sourcing needs and business models. Pharma ChemOutsourcing draws perhaps the largest assembly of biotech chemists and CMC professionals of any world meeting.

Exhibitors specializing in custom synthesis of API's, advanced intermediates, and a wide array of support services will be on hand. The exhibition is capped at 100 booths to ensure the intimate
'/>"/>

SOURCE Apaporis, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
2. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
7. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
8. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
11. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Cord Blood Corporation (NYSE: CO ) ("CCBC," the "Company," ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... Special Committee of the Company,s board of directors (the "Special ... ) Limited as its independent financial advisor, Cleary ... United States legal counsel and Maples & Calder ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 German-based Moenninghoff ... United States distributor for the Moenninghoff product line ... “I am pleased to announce that the R.M. Hoffman ... For our firm, founded in 1916, this is a ... Hoffman is the kind of professional distributor we need ...
(Date:6/1/2015)... South Korea , June 1, 2015 ... Inc. (GCBT) kicked off construction today on its biopharmaceutical ... Saint-Laurent Campus. The CA$315 million project represents one of ... Canada in the biopharmaceutical industry, giving place ... and albumin manufacturing plant in Canada ...
(Date:6/1/2015)... HANOVER, N.J. , June 1, 2015 /PRNewswire/ ... II clinical study of CTL019, an investigational chimeric ... its potential in the treatment of specific types ... study conducted by the University of Pennsylvania,s Perelman ... or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... , BIRMINGHAM, Ala. , Jan. 19 ... when it comes to cholesterol. According to a new study, a ... — can be labeled "bad cholesterol." The landmark study Genetic ... published in the New England Journal Of Medicine provides ...
... , , NEW HAVEN, Conn. , ... today that it has appointed Dr. Richard J. Carroll ... Research. , Dr. Carroll brings to HistoRx over 20 years ... diagnostic, pharmaceutical and medical device industries. Before joining HistoRx in ...
... CITY, China , Jan. 19 /PRNewswire-Asia-FirstCall/ -- ... fully,integrated and highly innovative biopharmaceutical company engaged in the,research and ... today announced financial results for the second quarter ended, November ... 2010 Highlights, -- Total revenue increased by ...
Cached Biology Technology:New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 2New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 3HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3Sinobiopharma Announces Second Quarter 2010 Financial Results 2Sinobiopharma Announces Second Quarter 2010 Financial Results 3Sinobiopharma Announces Second Quarter 2010 Financial Results 4
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... 2015  For more than four decades, AUVSI,s ... the premier worldwide event for the unmanned land, sea, ... event for any local, national, or trade news organization ... markets and current applications of unmanned technologies. The conference ... $48 billion industry, and how it will soon impact ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... 18, 2009 Pharmaceuticals and personal care products (PPCPs) ... reach surface waters or groundwater when these materials ... the high flow conditions created by land application ... of solutes in soil macropores may be too ...
... radiation therapy treatment damages a patient,s healthy tissue as ... destroy, making the treatment especially invasive and often causing ... will enable a far more precise and accurate treatment ... the radiation beam. Real-time image-guided radiotherapy, combining radiation ...
... available in French . , Montreal, May ... known to humans, and its abuse has become widespread since ... we know rather little about its effects on the human ... latest article by Dr. Marco Leyton, of the Montreal Neurological ...
Cached Biology News:Simulating pharmaceutical and personal care product transport 2Cocaine: Perceived as a reward by the brain? 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
...
Antibody Diluent for IHC 125 ml...
Biology Products: